MNG1034
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TGF_BETA_SIGNALING+0.500
- PROTEIN_SECRETION+0.466
- MYC_TARGETS_V1+0.386
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.357
- ANDROGEN_RESPONSE+0.320
- OXIDATIVE_PHOSPHORYLATION+0.311
- HEDGEHOG_SIGNALING+0.287
- UNFOLDED_PROTEIN_RESPONSE+0.268
- PEROXISOME+0.266
- ADIPOGENESIS+0.258
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.374
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.327
- ALLOGRAFT_REJECTION-0.308
- E2F_TARGETS-0.301
- INTERFERON_GAMMA_RESPONSE-0.296
- IL6_JAK_STAT3_SIGNALING-0.245
- G2M_CHECKPOINT-0.219
- INFLAMMATORY_RESPONSE-0.184
- PANCREAS_BETA_CELLS-0.163
- KRAS_SIGNALING_DN-0.140
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG1007 | — | — | 0.836 |
| 2 | MNG1056 | — | — | 0.826 |
| 3 | MNG579 | — | — | 0.809 |
| 4 | MNG1024 | — | — | 0.802 |
| 5 | 56D3154E-E779-4C27-8305-FEE7310B6762 | — | — | 0.786 |
| 6 | D1BFDB5B-3131-4B5C-8090-B3B91D4450F3 | — | — | 0.784 |
| 7 | BS_4NF35AF6 | low-grade glioma | — | 0.778 |
| 8 | MNG1071 | — | — | 0.769 |
| 9 | TCGA-BH-A0BS-01A-11R-A12P-07 | — | B | 0.768 |
| 10 | MNG1053 | — | — | 0.752 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 28 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TGF_BETA_SIGNALING | 0.500 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.466 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.386 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.357 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.320 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.311 | Remibrutinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.287 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.268 | Idelalisib | — uncovered |
| PEROXISOME | 0.266 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.258 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.226 | Temsirolimus | — uncovered |
| NOTCH_SIGNALING | 0.221 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.206 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.201 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.193 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.192 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.166 | Remibrutinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.142 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.132 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.118 | Inavolisib | — uncovered |